ClinicalTrials.gg
CompletedNCT03318276Updated Sep 20, 2019

Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

A Phase 3 interventional study of SID142 and Rinexin® Tab in Peripheral Arterial Disease, sponsored by SK Chemicals Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.

Sponsored by SK Chemicals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2017, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of — 9 open to participants now, 9 under way, 2 of them phase 3. Peripheral Arterial Disease · Korea, Republic of.

Enrollment
20th of 31
170 · median 230
Started
2017
with 2 others
Phase 3
8 of 41
1 open now
Registered
21st of 41
by date

Among the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2017, is one of 8 in phase 3, and was the 21st registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

9 of the 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Peripheral Arterial Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) has been widely used as an anti-platelet agent for the treatment of PAD. SID142 is a new controlled-release product improved patient's convenience and disadvantage of dosage regimen of previous drug. The aim of this study was to compare the efficacy and safety of SID142 and Rinexin® Tab in patients with PAD

Read the detailed description

This clinical trial is 12 weeks, multicenter, randomized, double-blind, parallel group, phase 3 study which registered patients in total 19 institutions appointed as national clinical trial institution, it was conducted by receiving IRB(institutional review board) approval from each institutions.

Target patients were aged over 20 years old male or female lower limb peripheral artery occlusion patients with fontaine stage II/III, who has lower limb pain. Lower limb pain degree is over 40 mm evaluated by VAS at screening, and ABI (ankle-brachial index) ≤0.9 or stenosis rate over >50%, diagnosed with PAD and voluntarily agreed to participate in clinical study and signed study consent form. Study subjects who met subjects criteria and recruited were total 170 subjects. Selected subjects were stratified by 1:1 ratio and randomly assigned to investigational product or comparator.

Investigational product was SID142 and comparator was Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg). Administration period to subjects was 12 weeks, study group took investigational product, SID1421 tab once(morning) and took placebo 1 tab/once, 2 times/day, and comparator group took investigational product, Rinexin® Tab 1 tab/once, 2 times/day and took placebo 1 tab once(morning).

Efficacy and Safety Assessment Parameter Subjects visited at 4, 8, and 12 weeks including baseline visit (visit 2) at 4 weeks interval and took efficacy and safety.

Variation in lower limb pain (VAS) comparing baseline with 12 weeks point as a primary efficacy Assessment parameter, variation in lower limb pain (VAS) comparing baseline with 4, 8 weeks, ankle brachial pressure index (ABI), ankle systolic pressure (ASP), Maximum Walking Distance (MWD), Pain Free Walking Distance (PFWD), andInvestigator's global assessment (5-point scale) as secondary efficacy assessment parameters, efficacy was measured. Pain and coldness test was measured using pain and coldness felt by subject 24 hours prior to the visit, MWD and PFWD was measured only on subjects who was determined to be possible to measure. Also, adverse event, laboratory test, vital sign, were conducted for safety assessment. Physical test and vital sign were conducted at screening visit, administration begins, 4, 8, and 12 weeks and urine pregnancy test and laboratory test were conducted at screening visits and 12 weeks. ECG test was conducted at screening visit, 4, 8, and 12 weeks after. Laboratory test criteria were hematological test, blood chemical test, blood coagulation test and urine test.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female outpatients over 20years of age
  2. patients confirmed to have PAD

    • ABI ≤0.9
    • Occlusion rate>50%
  3. LE PAD with Fontaine stage II/III
  4. LE pain VAS≥40mm at screening

Exclusion criteria

Exclusion Criteria:

  1. Patients who underwent vascular surgery or endovascular procedure for PAD within 1month prior to study. Patients who need vascular surgery or endovascular procedure for PAD during this study also should be excluded.
  2. Patients with peripheral neuropathy.
  3. Patients with ischemic heart diseases or underwent percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months prior to study.
  4. Patients who has diagnosed cerebrovascular diseases within 6 months prior to study.
  5. Patients with hemorrhage or predisposition to hemorrhage at screening visit.
  6. Uncontrolled hypertension defined as ≥ 180 mmHg of systolic blood pressure or ≥ 110 mmHg of diastolic blood pressure
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    SID142

    Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks

    Drug: SID142

  • Active comparator
    Rinexin® Tab

    Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks

    Drug: Rinexin® Tab

Interventions

  • DrugSID142

    SID142 is administrated to patients with PAD for 12 weeks

    Also known as: Placebo (For Rinexin® Tab)

  • DrugRinexin® Tab

    Rinexin® Tab is administrated to patients with PAD for 12 weeks

    Also known as: Placebo (For SID142)

06

What researchers measure

Primary outcomes

  1. Variation in lower limb pain (VAS)

    A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure lower limb pain that is believed to range across a continuum of values. The amount of pain that a subject feels ranges across a continuum from none to an extreme amount of pain. VAS is a 100mm horizontal line. The patient marks on the line the point that they feel represents their perception of their state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the subject marks. The higher the score, the more severe the pain.

    Time frame: 12 weeks

07

Study locations

1 site
  • Yonsei University College of Medicine, Severance Cardiovascular Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kook H, Yu CW, Choi D, Ahn TH, Chang K, Cho JM, Kim SJ, Park CG, Cho DK, Kim SH, Lee HC, Jin HY, Chae IH, Kwon K, Ahn SG, Kim JH, Lee SR, Kim JS, Kim SY, Lim SW. Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial. Clin Ther. 2022 Apr;44(4):508-528. doi: 10.1016/j.clinthera.2022.01.016. Epub 2022 Apr 9. PubMed 35410753 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Oct 2018, 19 months.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2017
First posted
Oct 23, 2017
StartActual
Feb 20, 2017
Primary completionActual
Oct 15, 2018
CompletionActual
Oct 15, 2018
Last update
Sep 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03318276
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
Feb 20, 2017
Primary completion
Oct 15, 2018
Completion
Oct 15, 2018
Last update
Sep 20, 2019

Study contacts

Donghoon Choi
principal investigator · Yonsei University College of Medicine, Severance Cardiovascular Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion